Surrogacy Case Study: Prostate Specific Antigen (PSA ... - Isped

More documents

Recommendations

Info

Kaplan-Meier curve of overall survival in ASCENT trial Beer, T. M. et al. J Clin Oncol; 25:669-674 2007
Be aware of your drug’s effect on the marker Broken Arrow (Immuno, APC8501) No effect (anti-angiogenic drug as sorafeni Start of Therapy Lead In Post-therapy Delayed effect (Differentiating agent) Rapid decline (HT, CT, Suramin) Scher et al.
Page 1 and 2: EORTC Surrogacy Case Study: Prostat
Page 3 and 4: Prostate Specific Antigen (PSA) •
Page 5 and 6: Transition between clinical states
Page 7 and 8: Surrogate endpoint • An outcome m
Page 9 and 10: Meta-analytic validation First stag
Page 11 and 12: PSA - defined endpoints in prostate
Page 13 and 14: PSA “surrogacy” studies in the
Page 15 and 16: Published PSA surrogacy studies Col
Page 17 and 18: Review • 2 meta-analytic validati
Page 19 and 20: PSA endpoints PSA normalization A P
Page 21 and 22: PSA data (M1) Mean log(PSA) -2 0 2
Page 23 and 24: Treatment effects on OS against tre
Page 25 and 26: Prediction for a new trial - M1 •
Page 27 and 28: PSA doubling-free survival (PSA-D)
Page 29 and 30: Recommendation, M1 hormone sensitiv
Page 31 and 32: 4m vs 24m ADT adjuvant to irradiati
Page 33 and 34: PSA-DT and TTBF surrogate for PCa-s
Page 35 and 36: PSA response or PSA-V surrogate for
Page 37 and 38: Of interest… The search for the g
Page 39 and 40: Conclusions for HRPC on chemotherap
Page 41: ASCENT trial High dose Calcitriol (

Surrogacy Case Study: Prostate Specific Antigen (PSA ... - Isped

Create successful ePaper yourself

Delete template?

Save as template?